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Novel mutation in addition to functional TMPRSS6 gene 
polymorphisms originate an IRIDA-like phenotype in an African child
Iron-refractory iron deficiency
anemia (IRIDA) is a hereditary rare
autosomal recessive anemia often
unresponsive to oral iron intake and
partially responsive to parenteral
iron treatment. 1
The disease originates from
mutations in TMPRSS6 gene,
encoding Matriptase-2, a
transmembrane serine protease that
plays an essential role in down-
regulating hepcidin (Figure 1). 1,2
Once TMPRSS6 is mutated, the
corresponding protein is absent or
inactive at the hepatocyte
membrane leading to uncontrolled
high levels of hepcidin and impaired
iron absorption. 3
Introduction Material and Methods
Results and Discussion
This study aimed to investigate a 4-year-old boy of sub-Saharan ancestry (Mozambique/Angola),
presenting a microcytic hypochromic anemia, low transferrin saturation, normal ferritin, and
having a partial response to intravenous iron treatment (Table 1).
The subject is a -α3.7-thalassemia carrier. TMPRSS6 was screened for variants by Next-
Generation Sequencing using NexteraXT libraries in a MiSeq platform (Illumina).
Genetic variants found were validated by Sanger sequencing. In silico analyses were
performed in Poly-Phen2, Sorting Intolerant from Tolerant (SIFT) and Missense3D
softwares.
Hematologic and
biochemical
parameters 
Reference
values for 
1-4 years old
Patient
Iron treatment 
Before After
RBC  (x10^12/L) 3.50–5.30 4.51 4.38
Hb (g/dL) 10.7–15.1 9.8 10.2
Ht (%) 31.0–45.0 31.7 33.1
MCV (fL) 72.0–100.0 70.3 75.6
MCH (pg) 23.8–34.2 21.7 23.3
MCHC (g/dL) 31.6–34.9 30.9 30.8
RDW (%) 11.6–13.9 17.7 16.6
Fe  (µg/dL) 62-68 19 51
TIBC (μg/dL) 228-428 313 273
TSAT (%) 16.0-45.0 6.07 18.68
Ft (μg/L) 30.0-300.0 33.0 242.3
 DNA analysis - A novel missense mutation (c.871G>A) was found in heterozygosity, in
TMPRSS6 exon 8. Additionally, 3 SNPs previously associated with a greater risk of
developing iron deficiency anemia (K253E, V736A and Y739Y) were also identified in
TMPRSS6 (Figure 2). At protein level, the novel variant gives rise to the G291S
mutation, located at the first CUB1 domain, which suggests it may affect the enzyme
activation and substrate recognition (Figure 2).
 Although IRIDA is known as an autosomal recessive disease, in this case, the result of a digenic inheritance of the novel damaging mutation (c.871G>A; G291S), three
common modulating SNPs in the same gene and the co-inheritance of the α-thalassemia HBA deletion may lead to an IRIDA-like phenotype.
 Further functional studies of the mutated protein as well as family studies should be conducted.
Conclusions
Figure 1. Matriptase-2 (circled in blue) regulates cellular iron export:
(1) Dietary iron and iron recycled from erythrocytes are stored in
enterocytes and splenic macrophages and are released to the circulation
through ferroportin;
(2) Hepcidin produced by hepatocytes binds to ferroportin and targets the
channel for degradation;
(3) Hepcidin gene (HAMP) expression is positively regulated by bone
morphogenic protein BMP6, which signals through the BMP receptor
(BMPR)-SMAD pathway in a hemojuvelin-dependent manner. Matriptase-2
continuously degrades hemojuvelin, which reduces hepcidin synthesis
and allows appropriate ferroportin iron cellular export from enterocytes
and macrophages to the bloodstream.2
MissenseSynonymous
D521=
V736A
Y739=Pr33=
G291S
K253E S361=
Y418=
Aims
Table 1: Hematologic parameters and iron status of the
patient before and after intravenous iron treatment in
comparison to reference values.
Figure 2: Schematic model of Matriptase-2. Structurally, Matriptase-2 contains a short N-terminal
cytoplasmic domain, a membrane-spanning region (TM), one SEA domain, two CUB domains, three
LDLa domains, and a trypsin-like serine protease domain. Coding region mutations are indicated by
arrows. The novel G291S mutation is highlighted in yellow. Adapted from Lee et al. 2009 4
Figure 3. Results from in silico analysis showing potential damage to the protein structure and stability:
(a) Poly-Phen2, that takes into consideration differences between human proteins and homologous proteins
in other mammals (score = 1; probably damaging);
(b) SIFT, that predicts whether an amino acid substitution affects protein function based on sequence
homology and the physical properties of amino acids (score = 0; deleterious);
(c) Missense3D, that perceives the importance of an amino acid based on 3D structure of the whole protein.
In order to run the Missense3D analysis, we predicted a 3D structure for Matriptase-2 in the software
Phyre2iro [cavity altered; Gly in a bend].
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 In silico analysis - Indicates the conserved amino acid change (G291S) may be damaging to 
the protein structure and stability (Figure 3).  
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